<DOC>
	<DOCNO>NCT01331317</DOCNO>
	<brief_summary>The primary objective ass impact three month treatment active vitamin D analogue risk marker excess overall mortality cardiovascular morbidity/mortality Type 1 diabetic patient diabetic kidney disease . The hypothesis active vitamin D analogue treatment reduces risk cardiovascular morbidity mortality patient type 1 diabetic kidney disease .</brief_summary>
	<brief_title>Effect Vitamin D Analogue v Placebo p-NT-proBNP Patients With Type 1 DM Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1875 year age Type 1 diabetes mellitus Diabetic nephropathy ( defined persistent albuminuria , &gt; 300 mg/24 hr 200Âµg/min 2 3 consecutive sample , presence diabetic retinopathy absence clinical laboratory evidence kidney renal tract disease Chronic kidney disease stage 3 4 SParathyroid hormone ( sPTH ) &gt; 35pg/ml Stabile RAASblocking diuretic treatment Other kidney disease diabetic nephropathy Myocardial infarction within last three month prior visit 1 Coronary artery revascularization within last three month prior visit 1 Transitional cerebral ischemia ( TCI ) apoplexia within last three month prior visit 1 Cardiac Failure ( NYHA Class III IV ) Kidney Failure ( GFR &lt; 15ml/min ) , dialysis , kidney transplantation ) Liver disease serum alanine aminotransferase ( ALT &gt; 3 x normal value Alcohol/drug abuse Hypercalcemia ( serum ionize calcium &gt; 1.35 mmol /L ) Medication phosphate and/or vitamin Dcontaining medication , pause study Clinical sign vitamin D toxicity Pregnant nursing woman Fertile woman use chemical mechanical ( IUD ) contraceptive method Current disulfiram treatment Allergy study drug Patient unable understand inform consent Any condition therapy , opinion investigator , make patient suited participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cardiovascular disease mortality</keyword>
	<keyword>Plasma NTproBNP</keyword>
	<keyword>UAER</keyword>
</DOC>